Statement of Cash Flows

3 Months Ended

Mar. 31, 2021

Cash and Cash Equivalents [Abstract]

Statement of Cash Flows

Statement of Cash Flows

The following provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheet to the total of the same such amounts shown in the Condensed Consolidated Statement of Cash Flows:

	March 31,
(In millions)	2021		2020
Cash and cash equivalents	$	1,437.9	$	2,208.2
Restricted cash included in Other noncurrent assets	12.5		12.5
Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows	$	1,450.4	$	2,220.7

Restricted cash consists of amounts held by financial institutions pursuant to contractual arrangements.

Supplemental disclosure of non-cash investing and financing activities

The following amounts were included in accounts payable, accrued expenses, and other liabilities:

	March 31,		December 31,		March 31,		December 31,
(In millions)	2021		2020		2020		2019
Accrued capital expenditures	$	75.6	$	83.6	$	72.6	$	133.7

As described in Note 10, during the three months ended March 31, 2020, we purchased (by issuing a credit towards the amount owed by Sanofi) shares of our Common Stock from Sanofi to satisfy Sanofi's funding obligation related to Libtayo development costs.